Hemodynamic Completes Initial Phase 2 Clinical Study For Combination Hypertension Therapy

Hemodynamic has completed its initial Phase 2 clinical study of its compound (HTI-101), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.

The 12-week double-blind placebo controlled Phase 2 study investigated the effects of a low dose combination of amiloride HCl and spironolactone in obese adults with treatment-resistant hypertension and met its primary endpoint. HTI was assisted in the execution of this trial by Cato Research, a contract research and development organisation that is affiliated with Cato BioVentures.

Daniel Pharand, CEO of HTI, said: “HTI remained as virtual as possible during these challenging economic times and to do this we have strategically leveraged the clinical and regulatory expertise of Cato Research in reaching this important clinical milestone for the company.”

Obese patients were enrolled in the study with all experiencing uncontrolled hypertension while taking three or more anti-hypertensive medications. After only one month of treatment with HTI101, there was a significant decrease in both systolic and diastolic blood pressure.

Allen Cato, CEO of Cato Research, said: “We are pleased to see such a strong response of HTI-101 in this important patient population and feel that this could be a new tool for treating unabated hypertension.”

HTI obtained the core technology through an exclusive patent, a license agreement with the University of Alabama Research Foundation (UABRF).